MedTrace Logo

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-06-10

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer.

The drugs involved in this study are:

* EGF816
* Gefitinib

Conditions

Interventions

DRUG

EGF816

EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

DRUG

Gefitinib

Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Zofia Piotrowska, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2021-12-31
Completion
2025-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292133 on ClinicalTrials.gov